D019892Chemicals & DrugsD08.811.913.696.620.682.700.300D12.644.360.275D12.776.476.27529460.969798eIF-2 Kinaseprns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation Resourcevivo:linkAnchorTextlink anchor textPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forURLLinkvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson30923003Dzhashiashvili Y, Monckton CP, Shah HS, Kunjamma RB, Popko BNeurobiology of diseaseThe UPR-PERK pathway is not a promising therapeutic target for mutant SOD1-induced ALS. Neurobiol Dis. 2019 07; 127:527-544.Neurobiol Dis2019-03-26T00:00:002019The UPR-PERK pathway is not a promising therapeutic target for mutant SOD1-induced ALS.30952841Jin HR, Du CH, Wang CZ, Yuan CS, Du WCell death & diseaseGinseng metabolite Protopanaxadiol induces Sestrin2 expression and AMPK activation through GCN2 and PERK. Cell Death Dis. 2019 04 05; 10(4):311.Cell Death Dis2019-04-05T00:00:002019Ginseng metabolite Protopanaxadiol induces Sestrin2 expression and AMPK activation through GCN2 and PERK.ScottOakesScott Oakes41.7886000000000087.598699999999993838Oakes, ScottProfessor31672843Moore PC, Qi JY, Thamsen M, Ghosh R, Peng J, Gliedt MJ, Meza-Acevedo R, Warren RE, Hiniker A, Kim GE, Maly DJ, Backes BJ, Papa FR, Oakes SACancer researchParallel Signaling through IRE1a and PERK Regulates Pancreatic Neuroendocrine Tumor Growth and Survival. Cancer Res. 2019 12 15; 79(24):6190-6203.Cancer Res2019-10-31T00:00:002019Parallel Signaling through IRE1a and PERK Regulates Pancreatic Neuroendocrine Tumor Growth and Survival.Medicine-Pulmonary and Critical Care1.081710.0079862329research area of0.7365890.026754248subject area forRobertHamanakaRobert Hamanaka0.000000000000000.000000000000003124Hamanaka, RobertResearch Associate Professorhttp://pathology.uchicago.eduUChicago Dept of Pathologyhttp://www.oakeslab.uchicago.eduOakes Lab WebsiteMedicineBSD MicrobiologyPathologyUniversity of ChicagoBernardRoizman1Wd7BaAHHaLLnnN+bUfg02fp+4Wo6r1Xc3h9eaOOFmI=Bernard Roizman41.78927490000000-87.601250000000001112Roizman, BernardEmeritus/Emerita, ProfessorHansSchreiberHans Schreiber41.78927490000000-87.601250000000001921Schreiber, HansProfessorRaviSalgiaRavi Salgia41.78927490000000-87.601250000000001937Salgia, RaviEmeritus/Emerita, Professortrue1Emeritus/Emerita, ProfessorEmeritus/Emerita, Professortrue1Emeritus/Emerita, ProfessorEmeritus/Emerita, Professortrue1Research Associate ProfessorResearch Associate Professortrue1ProfessorProfessortrue1ProfessorProfessor26667491Leisegang M, Engels B, Schreiber K, Yew PY, Kiyotani K, Idel C, Arina A, Duraiswamy J, Weichselbaum RR, Uckert W, Nakamura Y, Schreiber HClinical cancer research : an official journal of the American Association for Cancer ResearchEradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation. Clin Cancer Res. 2016 06 01; 22(11):2734-43.Clin Cancer Res2015-12-14T00:00:002015Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation.27480287Won B, Mambetsariev I, Salgia RBMC cancerPost-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer. BMC Cancer. 2016 08 02; 16:568.BMC Cancer2016-08-02T00:00:002016Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.